Genevive Hernandez
Sutro Biopharma (United States)(US)
Publications by Year
Research Areas
Monoclonal and Polyclonal Antibodies Research, CAR-T cell therapy research, Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, Glycosylation and Glycoproteins Research
Most-Cited Works
- → Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma(2016)702 cited
- → Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients(2019)234 cited
- → Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors(2019)188 cited
- → Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines(2019)179 cited
- → Anti-VEGF Treatment Enhances CD8+ T-cell Antitumor Activity by Amplifying Hypoxia(2020)98 cited
- → Activation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation(2021)97 cited
- → Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC).(2017)70 cited
- → Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study(2018)59 cited
- → Systems‐based digital twins to help characterize clinical dose–response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL(2023)56 cited
- → Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199(2021)49 cited